Randomized Phase II Study on the Additive Effect of Everolimus in Post-Menopausal Patients with Endocrine Therapy-Sensitive ER-Positive HER2-Negative Metastatic Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 13 Oct 2017
Price : $35 *
At a glance
- Drugs Everolimus (Primary) ; Aromatase inhibitors
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms Chloe
- 13 Oct 2017 New trial record
- 08 Sep 2017 Trial design presented at 42nd European Society for Medical Oncology Congress.
- 26 Apr 2017 Status changed from not yet recruiting to recruiting.